Trial · NCT07898852
Integrated Psychoeducation Program for Internalized Stigma in Schizophrenia
NCT07898852, Not applicable, Not yet recruiting, Dokuz Eylul University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Integrated Psychoeducation Program for Internalized Stigma in Schizophrenia. Trials, record NCT07898852. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07898852
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Integrated Psychoeducation Program for Internalized Stigma in Schizophrenia
- NCT number
- NCT07898852
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Dokuz Eylul University
- Conditions
- Schizophrenia, Schizoaffective Disorder, Internalized Stigma, Social Stigma
- Interventions
- Integrated Psychoeducation Program
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in internalized stigma (ISMI total score) | Baseline (before randomization) and post-intervention (Week 8) | Internalized stigma measured with the Internalized Stigma of Mental Illness (ISMI) scale, Turkish version (29 items, 4-point Likert scale). Higher scores indicate greater internalized stigma. |
| Secondary | Change in self-esteem (RSES) | Baseline and post-intervention (Week 8) | Self-esteem measured with the Rosenberg Self-Esteem Scale (RSES), Turkish version. Lower scores indicate higher self-esteem. |
| Secondary | Change in hopelessness (BHS-7) | Baseline and post-intervention (Week 8) | Hopelessness measured with the 7-item short form of the Beck Hopelessness Scale (BHS-7), Turkish version. Higher scores indicate greater hopelessness. |
| Secondary | Change in psychological flourishing (Flourishing Scale) | Baseline and post-intervention (Week 8) | Psychological flourishing measured with the Flourishing Scale (Diener et al., 2010), Turkish version (Psychological Well-Being Scale; Telef, 2013) (8 items, 7-point Likert scale; total score 8-56). Higher scores indicate greater psychological flourishing. |
| Secondary | Internalized stigma at 3-month follow-up (ISMI) | Baseline, post-intervention (Week 8), and 3 months after the post-test | ISMI total score at 3-month follow-up compared with baseline and post-intervention. |
| Secondary | Self-esteem at 3-month follow-up (RSES) | Baseline, post-intervention (Week 8), and 3 months after the post-test | RSES score at 3-month follow-up compared with baseline and post-intervention. |
| Secondary | Hopelessness at 3-month follow-up (BHS-7) | Baseline, post-intervention (Week 8), and 3 months after the post-test | BHS-7 score at 3-month follow-up compared with baseline and post-intervention. |
| Secondary | Psychological flourishing at 3-month follow-up (Flourishing Scale) | Baseline, post-intervention (Week 8), and 3 months after the post-test | Flourishing Scale score at 3-month follow-up compared with baseline and post-intervention. |
| Secondary | Session attendance rate | Weeks 1-8 | Mean percentage of the 8 sessions attended by participants in the intervention group. |
| Secondary | Program completion rate | Weeks 1-8 | Percentage of participants in the intervention group who attend at least 6 of the 8 sessions. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07898852
GET https://conductscience.org/api/trials/v1/NCT07898852/registered